Co-Authors
This is a "connection" page, showing publications co-authored by David Cole and Ernest Camp.
Connection Strength
0.755
-
The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. Oncogenesis. 2016 Jan 11; 5:e182.
Score: 0.141
-
The impact of surgical diversion before neoadjuvant therapy for rectal cancer. Am Surg. 2015 May; 81(5):444-9.
Score: 0.134
-
The impact of lymph node disease in extremity soft-tissue sarcomas: a population-based analysis. Am J Surg. 2013 Sep; 206(3):289-95.
Score: 0.118
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.116
-
The role of sentinel lymph node biopsy in select sarcoma patients: a meta-analysis. Am J Surg. 2012 Oct; 204(4):428-33.
Score: 0.109
-
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
Score: 0.106
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
Score: 0.031